New England Accountable Care Group Selects Gold Standard Drug Database

Elsevier’s Gold Standard will provide NNEACC with essential drug information in a streamlined database solution

Tampa, FL, November 5, 2012 Elsevier’s Gold Standard, a leading drug information provider, announced today that the Northern New England Accountable Care Collaborative, LLC (NNEACC), composed of Eastern Maine Healthcare Systems, Dartmouth-Hitchcock Health, MaineHealth and Dartmouth College, has selected the Gold Standard Drug Database to deliver current and accurate drug data and drug decision support. The integration of the Gold Standard Drug Database module will allow the NNEACC to streamline and automate the process of integrating prescribing data with administrative and clinical information to provide a robust view of patient activity to clinicians.

The Gold Standard Drug Database will offer NNEACC drug pricing updates, therapeutic groupings of drug products, brand versus generic identifiers, and accurate information on generics. The Gold Standard Drug Database interacts intelligently with patient prescribing data to guide the clinician to an efficient and effective delivery of the patient’s medication, assisting adherence to drug therapy for best health benefits. NNEACC will benefit from the database’s modern technical architecture, combined with current, accurate content and built-in human logic for superior decision support, which distinguishes Gold Standard Drug Database from other drug compendia.
"
“The Gold Standard Drug Database will significantly enhance the way we receive and interpret drug information, administration and pricing,” said Dr. David Wennberg, CEO of NNEACC. “This database will give us access to the most current and accurate drug data and decision support.”

NNEACC was co-founded by Dartmouth-Hitchcock Health, Eastern Maine Healthcare Systems, MaineHealth and Dartmouth College to develop, implement and evaluate new models of clinical care required to achieve the triple aim of improved population health, improved quality and satisfaction of the patient experience and reduced per capita costs. Led by Dr. David Wennberg, the NNEACC solution integrates administrative and clinical data sources in a proven data technology foundation with innovative analytics to provide focused and actionable information that supports clinicians and administrators as they manage care.

“We look forward to providing NNEACC with the critical information needed to streamline drug information and improve the efficiency of daily processes,” said Marianne Messer, President of Elsevier’s Gold Standard.  “Our innovative clinical decision support solutions enable us to provide drug information rapidly and effectively to ensure that the NNEACC will have the latest and best information, ultimately assisting in better care.”

For more information about NNEACC, please visit www.nneacc.com.

For more information about Elsevier’s Gold Standard, please visit www.goldstandard.com.


# # #

Elsevier’s Gold Standard
Based in Tampa, FL, Elsevier’s Gold Standard uses innovative technologies to provide a complete suite of drug information and decision support solutions. With a tenacious commitment to product quality, Elsevier’s Gold Standard solutions empower healthcare organizations, professionals and consumers to meet the most pressing healthcare challenges, improve patient safety and ensure optimal outcomes. To learn more about Elsevier’s Gold Standard, visit www.goldstandard.com.

About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence,and ClinicalKey—and publishes over 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media contact
Christopher Capot
Director, Corporate Relations, Elsevier
+1 212 633 3164
c.capot@elsevier.com